Study Examines Multigene Panel Testing for Hereditary Breast, Ovarian Cancer Risk Assessment
CHICAGO -- August 13, 2015 -- Multigene testing of women negative for BRCA1 and BRCA2 found some of them harboured other harmful genetic mutations, most commonly moderate-risk breast and ovarian cancer genes and Lynch syndrome genes, which increase ovarian cancer risk, according to a study published online by JAMA Oncology.
Multigene panel genetic tests are increasingly recommended for patients evaluated for a predisposition to hereditary breast/ovarian cancer (HBOC). However, the rapid introduction of these tests has raised concerns because many of the tested genes are low- to moderate-risk genes for which consensus management guidelines have not been introduced or were introduced only very recently.
Leif W. Ellisen, MD, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, and colleagues wanted to determine how often multigene panel testing would identify mutations that warranted some clinical action among women appropriately tested but lacking BRCA1 and BRCA2 mutations.
The authors enrolled 1,046 women and carried out multigene panel testing on all the participants. Among the 1,046 women, 3.8% of them (40 women) who were negative for BRCA1 and BRCA2 had harmful mutations in other moderate-risk genes.
The authors included an additional 23 patients in the study’s clinical management analysis and results indicate that among 63 women positive for mutations, the majority of them (33 women [52%]) would be considered for additional disease-specific screening and/or prevention measures beyond those based on personal and family history alone. Additional family testing also would be considered for first-degree relatives, according to the results. In the large majority of mutation-positive cases (58 of 63 [92%]), personal and/or family histories included cancer associated with the mutant genes.
“Multigene panel testing for patients with suspected HBOC risk identifies substantially more individuals with relevant cancer risk gene mutations than does BRCA1/2 testing alone,” the authors wrote. “Identifying such mutations is likely to change management for the majority of these individuals and their families in the near term, and in the long term should lead to development of effective management guidelines and improved outcomes for at-risk individuals.”
In a related commentary, Elizabeth M. Swisher, MD, University of Washington Medical Center, Seattle, Washington, wrote: “I applaud Desmond et al for tackling this important and challenging question. Multigene testing is rapidly becoming the norm for genetic cancer risk assessment. We must continue to assess the effect of such testing on clinical care and patient experience and work to provide meaningful guidelines for cancer-preventive care for those with less common genetic findings.”
SOURCE: JAMA Oncology